Technical Analysis for LQDA - Liquidia Technologies, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 12.55 | -3.09% | -0.40 |
Earnings due: May 2
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Down 5 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | -3.09% | |
Down 4 Days in a Row | Weakness | -3.09% | |
Oversold Stochastic | Weakness | -3.09% | |
Inside Day | Range Contraction | -4.78% | |
Down 3 Days in a Row | Weakness | -4.78% |
Alert | Time |
---|---|
Fell Below Lower Bollinger Band | about 4 hours ago |
Down 3% | about 7 hours ago |
Down 2 % | about 9 hours ago |
60 Minute Opening Range Breakdown | about 9 hours ago |
Down 1% | about 9 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Liquidia Technologies, Inc. Description
Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Pharmaceutical Pain Medication Hypertension Clinical Trial Opioids Pulmonary Arterial Hypertension Uniform Bupivacaine Inhaler Treprostinil
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 16.99 |
52 Week Low | 5.71 |
Average Volume | 844,226 |
200-Day Moving Average | 9.87 |
50-Day Moving Average | 14.59 |
20-Day Moving Average | 14.38 |
10-Day Moving Average | 13.62 |
Average True Range | 0.77 |
RSI (14) | 31.97 |
ADX | 16.89 |
+DI | 14.49 |
-DI | 30.02 |
Chandelier Exit (Long, 3 ATRs) | 14.62 |
Chandelier Exit (Short, 3 ATRs) | 14.70 |
Upper Bollinger Bands | 16.24 |
Lower Bollinger Band | 12.51 |
Percent B (%b) | 0.01 |
BandWidth | 25.94 |
MACD Line | -0.51 |
MACD Signal Line | -0.26 |
MACD Histogram | -0.2548 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.55 | ||||
Resistance 3 (R3) | 13.62 | 13.34 | 13.39 | ||
Resistance 2 (R2) | 13.34 | 13.09 | 13.31 | 13.33 | |
Resistance 1 (R1) | 12.95 | 12.93 | 12.81 | 12.88 | 13.28 |
Pivot Point | 12.67 | 12.67 | 12.60 | 12.64 | 12.67 |
Support 1 (S1) | 12.28 | 12.42 | 12.14 | 12.22 | 11.82 |
Support 2 (S2) | 12.00 | 12.26 | 11.97 | 11.77 | |
Support 3 (S3) | 11.61 | 12.00 | 11.71 | ||
Support 4 (S4) | 11.55 |